Compare TYG & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TYG | GERN |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 891.7M | 1.0B |
| IPO Year | 2003 | 1996 |
| Metric | TYG | GERN |
|---|---|---|
| Price | $36.79 | $0.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.63 |
| AVG Volume (30 Days) | 129.3K | ★ 14.6M |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | ★ 15.88% | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,065,000.00 |
| Revenue This Year | N/A | $27.99 |
| Revenue Next Year | N/A | $44.91 |
| P/E Ratio | $52.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.23 | $0.84 |
| 52 Week High | $51.18 | $2.01 |
| Indicator | TYG | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 39.98 |
| Support Level | N/A | $0.84 |
| Resistance Level | $44.60 | $1.67 |
| Average True Range (ATR) | 1.15 | 0.09 |
| MACD | -0.17 | -0.00 |
| Stochastic Oscillator | 31.87 | 36.08 |
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.